Oric Pharmaceuticals Inc reports results for the quarter ended December 31 - Earnings Summary

• Oric Pharmaceuticals Inc ORIC.OQ reported a quarterly adjusted loss of 30 cents​​ per share for the quarter ended December 31, higher than the same quarter last year, when the company reported EPS of -51 cents. The mean expectation of sixteen analysts for the quarter was for a loss of 36 cents per share. Wall Street expected results to range from -51 cents to -35 cents per share.

• Reported revenue was zero​; analysts expected zero.

• Oric Pharmaceuticals Inc's reported EPS for the quarter was a loss of 30 cents​.

• The company reported a quarterly loss of $32.59 million.

• Oric Pharmaceuticals Inc shares had risen by 35.8% this quarter.

FORECAST CHANGES

• The mean earnings estimate of analysts had risen by about 0.2% in the last three months.​

• In the last 30 days, one analyst negatively revised an earnings estimate

RECOMMENDATIONS

• The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 14 "strong buy" or "buy," 1 "hold" and no "sell" or "strong sell." The average consensus recommendation for the biotechnology & medical research peer group is also "buy"

• Wall Street's median 12-month price target for Oric Pharmaceuticals Inc is $22.00, about 46.8% above its last closing price of $11.71

This summary was machine generated from LSEG data February 23 at 11:14 p.m. UTC. ​All figures in US dollars unless otherwise stated. (For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact RefinitivNewsSupport@thomsonreuters.com)